Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Philippines weighs...

    Philippines weighs re-use of Sanofi controversial dengue vaccine Dengvaxia

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-08-03T09:14:39+05:30  |  Updated On 17 Aug 2021 10:11 AM IST

    The Philippines stopped using Dengvaxia in late 2017 and ordered Sanofi to stop selling, distributing and marketing it after Sanofi warned the vaccine could worsen the disease in some cases.


    MANILA: The Philippines is considering re-introducing a dengue vaccine whose use it halted because of links to the deaths of several children, as authorities battle to contain a dengue outbreak that has killed more than 450 people this year.


    Concerns over dengue immunization for nearly 734,000 children aged nine or older sparked two congressional inquiries, a criminal investigation and a sharp fall in the number of parents seeking routine vaccinations for their children.


    If the government decided to revive the use of Dengvaxia, developed by French drugmaker Sanofi, it would be administered with "utmost caution", presidential spokesman Salvador Panelo said.


    "If Dengvaxia is proven effective to those who already had dengue in the past, then its application to these individuals will surely cause the decline of the overall number of cases," he told reporters.


    The Philippines stopped using Dengvaxia in late 2017 and ordered Sanofi to stop selling, distributing and marketing it after Sanofi warned the vaccine could worsen the disease in some cases.


    Also Read: Sanofi wins USFDA approval to sell dengue vaccine Dengvaxia in parts of US


    In March, the Department of Justice said it had found probable cause to indict Sanofi officials, and former and current Philippine health officials, over 10 deaths it said were linked to the use of Dengvaxia, which Sanofi has repeatedly said is safe and effective.


    Panelo said the government would follow a protocol set by the World Health Organization for all individuals to be screened before receiving the vaccine, to determine if they have ever been exposed to the infection.


    Any decision to start administering the vaccine again would not affect cases against individuals involved in the controversy, he added.


    This year, the Philippines has reported more than 100,000 cases of dengue, a mosquito-borne tropical disease that kills about 20,000 people annually and infects hundreds of millions.


    Also Read: Sanofi officials to be charged over dengue vaccine deaths

    criminal investigationdengu feverDengue vaccineDengvaxiaFrench drugmakermalariaMosquito Borne DiseasesPhilippinesSalvador PaneloSanofiWHOWorld Health Organization
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok